Search

Introduction: The National Psoriasis Foundation (NPF) published treat‐to‐target guidelines for psoriasis, yet their applicability in clinical practice remains unknown. Objectives: To estimate the proportion of psoriasis patients meeting the NPF's body surface area (BSA) 'target' (≤1%) and 'acceptable' (≤3%) response criteria and the cross‐sectional associations of these criteria with patient‐reported outcomes (PROs) in the Corrona Psoriasis Registry. Methods: Separately for three independent cross‐sectional cohorts of patients at the (i) enrolment, (ii) 6‐month and (iii) 12‐month visits, we calculated the proportion of patients with BSA ≤1% and ≤3%. Furthermore, we calculated odds ratios estimating the risk of PROs associated with not meeting criteria in the 6‐month cohort. Results: The enrolment, 6‐ and 12‐month cohorts included 2794, 1310 and 629 patients, respectively. At enrolment, 24% of patients had a BSA ≤ 1% and 41% a BSA ≤ 3%. In the 6‐month cohort, 43%/64% had a BSA ≤ 1%/BSA ≤ 3%. In the 12‐month cohort, 46%/69% of patients had a BSA ≤ 1%/BSA ≤ 3%. Patients not at target/acceptable criteria had higher odds for worse quality of life compared with those who were. Conclusion: While most patients at 6‐ and 12‐month visits were at the 'acceptable' response, less than half were at the 'target' response despite systemic therapy. There remain unmet needs to optimize psoriasis therapy and further validate current treat‐to‐target guidelines. [ABSTRACT FROM AUTHOR]

Background: Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a five‐item questionnaire developed to help identify PsA at an early stage. Objectives: To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores. Methods: This study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient‐reported outcomes were compared in Corrona PsO Registry patients with PEST scores ≥3 and <3 using t‐tests for continuous variables and chi‐squared tests for categorical variables; scores ≥3 may indicate PsA. Results: Of 1516 patients with PsO, 904 did not have dermatologist‐reported PsA; 112 of these 904 patients (12.4%) scored ≥3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores <3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment. Conclusions: Improved PsA screening is needed in patients with PsO because the validated PEST identified over one‐tenth of registry patients who were not noted to have PsA as having scores ≥3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health‐related quality of life and worse activity impairment. [ABSTRACT FROM AUTHOR]